Shares of CD47 front-runner Forty Seven (FTSV) have risen by 120% over the past year and by 525% over the past three months. Currently, this growing biotech firm sports a market capitalization of around $1.75 billion, with management executing quite efficiently on accessing financing in mid December with 4.86 million common shares priced at $35 per share (plus underwriter option) for gross proceeds of around $170 million.
Biotech Phoenix, a veteran of the industry who graciously offers insights in our Live Chat from time to time, got me interested in this name when